| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Vitamin D Levels Not Associated With Myalgia in Patients Taking Atorvastatin: Presented at ACC By Ed Susman ATLANTA -- March 17, 2010 -- Patients whose blood levels indicate they are deficient in vitamin D are no more likely to experience myalgia while being treated with atorvastatin than people with normal levels of vitamin D, researchers said here at the 59th Annual Scientific Sessions of the American College of Cardiology (ACC). In fact, researchers said that risk of myalgias -- at least among patients in the Treating to New Targets (TNT) study -- was low for all patients. “Myalgias occurred infrequently in the TNT study and it didn’t seem to differ between groups of patients with low levels of Vitamin D or those with high levels,” said Vera Bittner, MD, University of Alabama at Birmingham, Birmingham, Alabama on March 15. Dr. Bittner and colleagues reviewed vitamin D blood levels from 1,509 participants in TNT. In the study patients were treated with either 10 or 80 mg of atorvastatin. As with the main study, the average age of the patients was about 60 years and more than 80% of the participants were men; about 14% were smokers, 55% had hypertension, and about 16% were diabetic. About 12.2% of the 776 patients with normal vitamin D levels at baseline complained of myalgia and about 8.3% of the 733 patients with deficient levels of vitamin D said they had bouts of myalgia as well. After 1 year 9.7% of the patients with normal vitamin D said they had myalgias compared with 10.9% of those patients who were deficient in vitamin D. “None of those differences were statistically significant,” said Dr. Bittner. She also said that discontinuations for myalgia were less than 1.5% in all the groups tested, and were not significantly different. Dr. Bittner said that the lack of a finding of a vitamin D influence in this group of patients might have had to do with an 8-week run-in period that tested if patients tolerated atorvastatin 10 mg. In the main trial, out of more than 10,000 patients tested, she said 35 were excluded from the trial because they complained of myalgias during the run-in phase. Funding for this was provided by Pfizer. [Presentation title: Vitamin D Levels Do Not Predict Cardiovascular Events in Statin-Treated Patients With Stable Coronary Disease. Abstract 1168-367]
|